
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx Inc. has demonstrated robust growth in its commercial offerings, highlighted by a remarkable 32% average quarter-over-quarter sales increase for Carvykti over the past three years, alongside a significant year-over-year revenue growth of 214%. The increasing adoption of CAR T therapy among community physicians, rising from 29% to 47%, indicates a strengthening market presence and potential for broader accessibility to advanced treatments. Furthermore, the anticipated clinical efficacy of anito-cel alongside other promising data reinforces a positive outlook, with projections suggesting the potential for substantial market share and significant revenue generation by 2035.
Bears say
Arcellx Inc faces significant challenges due to high rates of Grade 3-4 infections observed in its clinical trial MajesTEC-1, which could hinder patient adoption and overall treatment success. Additionally, the company's market share estimates for its product anito-cel are in line with consensus figures, yet its projected sales figures for the CAR T market in myeloma are notably below consensus, indicating potential revenue shortfalls. Furthermore, barriers to patient access and adoption in community settings, coupled with uncertainties around the development of additional clinical candidates, suggest a compromised growth trajectory and contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares